Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Claros Diagnostics Inc.

This article was originally published in Start Up

Executive Summary

A point-of-care diagnostic instrument that had the advantages of a test strip device in terms of ease-of-use and rapid results along with ELISA-like capabilities for major diseases would make diagnosis routine within the course of a patient visit and would revolutionize diagnostic practices. Claros Diagnostics has developed just such a device which it hopes to sell to doctors' offices, initially for urological applications, beginning in 2009.

You may also be interested in...



Start-Up Previews (02/07)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Spine Devices: Looking for a Twist Rather than a Tweaks, features profiles of CoreSpine, Interventional Spine, and Paradigm Spine. Plus these Start-Ups Across Health Care: Claros Diagnostics, Cure Therapeutics, Enigma Diagnosics, Generic Medical Devices, and Nitec Pharma.

Start-Up Previews (02/07)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Spine Devices: Looking for a Twist Rather than a Tweaks, features profiles of CoreSpine, Interventional Spine, and Paradigm Spine. Plus these Start-Ups Across Health Care: Claros Diagnostics, Cure Therapeutics, Enigma Diagnosics, Generic Medical Devices, and Nitec Pharma.

Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse

Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products, to bring an immunodiagnostics business in-house, Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche, and by its calculations, now plays a close third to Abbott Laboratories in the overall in vitro diagnostics market.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel